Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Research Scholarships - Master's program

University of Manitoba

$27,000.00

Characterization of IFN-Lambda Immunobiology in Control and Ulcerative Colitis Human Gut Tissue

EF 2025-26

Résumé
Ulcerative colitis (UC) is a chronic disease affecting over 100,000 Canadians, with worldwide incidence rising. UC is characterized by a dysregulated immune system leading to life-long inflammation and pain. Although medications for ulcerative colitis exist, their effectiveness varies among patients, they do not provide a cure, and thus new drug targets still need to be found. Interferon lambda (IFN-L) is an immune protein which signals through a receptor made of IFN-LR1 and IFN-10RB. It is normally present to promote gut health and healing. Gut inflammation is much worse in mice without this protein. Much less is known for how IFN-L works in the human gut. Our lab has two new methods to study this; First, we have a new IFN-LR1 antibody that can help us detect where the receptor is found. Second, we can take human gut tissue and study how IFN-L affects the various cells in the lab when we can keep the tissue alive for 24 hours. We predict that IFN-L is unique because it not only helps the gut heal but can stop the immune cells that cause damage in UC. In this project, I will study fresh gut tissue biopsies from healthy donors and UC patients (equal number of male and female samples). I will measure IFN-LR1 protein levels in tissue-resident immune cells and see if there are differences between disease state and gut site. I will also profile how IFN-L signals in gut cells across healthy and UC tissue by looking at gene and protein changes. My results will provide new data in our understanding of human IFN-L gut biology and if IFN-L could be a future drug to restore gut health and improve the life of those living with UC.
Programme
Master's Award: Canada Graduate Research Scholarships - Master's program
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
573342
Name
Thapar Gunjan
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of IFN-Lambda Immunobiology in Control and Ulcerative Colitis Human Gut Tissue
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Research Scholarships - Master's program
Keyworddelim
Cytokines; Gastroenterology; Immunology; Inflammation; Inflammatory Bowel Disease; Interferon Lambda; Large Intestine; Signalling; Ulcerative Colitis
Abstract
Ulcerative colitis (UC) is a chronic disease affecting over 100,000 Canadians, with worldwide incidence rising. UC is characterized by a dysregulated immune system leading to life-long inflammation and pain. Although medications for ulcerative colitis exist, their effectiveness varies among patients, they do not provide a cure, and thus new drug targets still need to be found. Interferon lambda (IFN-L) is an immune protein which signals through a receptor made of IFN-LR1 and IFN-10RB. It is normally present to promote gut health and healing. Gut inflammation is much worse in mice without this protein. Much less is known for how IFN-L works in the human gut. Our lab has two new methods to study this; First, we have a new IFN-LR1 antibody that can help us detect where the receptor is found. Second, we can take human gut tissue and study how IFN-L affects the various cells in the lab when we can keep the tissue alive for 24 hours. We predict that IFN-L is unique because it not only helps the gut heal but can stop the immune cells that cause damage in UC. In this project, I will study fresh gut tissue biopsies from healthy donors and UC patients (equal number of male and female samples). I will measure IFN-LR1 protein levels in tissue-resident immune cells and see if there are differences between disease state and gut site. I will also profile how IFN-L signals in gut cells across healthy and UC tissue by looking at gene and protein changes. My results will provide new data in our understanding of human IFN-L gut biology and if IFN-L could be a future drug to restore gut health and improve the life of those living with UC.
Competitiondate
202512
Approvedterm2
1 yr 0 mth
Pinamesdelim
Thapar, Gunjan
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~